• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why RH Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket

    3/28/24 8:21:31 AM ET
    $ABTS
    $AKBA
    $AVTX
    $CC
    Computer Software: Programming Data Processing
    Technology
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABTS alert in real time by email

    Shares of RH (NYSE:RH) rose sharply in today’s pre-market trading following the release of quarterly results.

    RH posted weaker-than-expected results for its fourth quarter, but issued upbeat forecast. The company said it sees full-year 2024 demand growth of 12% to 14% and revenue growth of 8% to 10% on a year-over-year basis, according to data from Benzinga Pro.

    RH shares jumped 9.4% to $324.99 in pre-market trading

    Here are some other stocks moving in pre-market trading.

    Gainers

    • Avalo Therapeutics, Inc. (NASDAQ:AVTX) rose 256.6% to $16.94 in pre-market trading after the company announced it acquired a Phase 2-ready anti-IL-1β mAb, which it refers to as AVTX-009, through the acquisition of privately held AlmataBio.
    • Binah Capital Group, Inc. (NASDAQ:BCG) gained 149% to $23.65 in pre-market trading after dipping more than 20% on Wednesday.
    • Kidpik Corp. (NASDAQ:PIK) gained 49.5% to $4.89 in pre-market trading.
    • Kidpik recently regained compliance with the Nasdaq minimum bid price requirement.
    • Kintara Therapeutics, Inc. (NASDAQ:KTRA) shares rose 36.3% to $0.1220 in pre-market trading. Kintara Therapeutics announced expansion of REM-001 clinical study to include patients on pembrolizumab.
    • Cazoo Group Ltd (NASDAQ:CZOO) gained 32.2% to $16.60 in pre-market trading after jumping over 100% on Wednesday.
    • Akebia Therapeutics, Inc. (NASDAQ:AKBA) shares rose 25% to $2.80 in pre-market trading. Akebia's received the FDA approval of Vafseo® tablets for dialysis-related anemia treatment.
    • Longeveron Inc. (NASDAQ:LGVN) gained 17% to $3.66 in pre-market trading. Longeveron’s board recently approved a 1-for-10 reverse split of Class A common stock.
    • 22nd Century Group, Inc. (NASDAQ:XXII) climbed 14.1% to $0.15 in pre-market trading. 22nd Century Group is expected to report quarterly earnings today.
    • GigaCloud Technology Inc. (NASDAQ:GCT) shares rose 9% to $28.50 in pre-market trading. GigaCloud Technology filed annual report on Form 10-K for fiscal year 2023.

    Losers

    • GCT Semiconductor Holding Inc, (NYSE:GCTS) dipped 21.2% to $34.68 in pre-market trading amid volatility following the company's recently completed business combination with Concord Acquisition Corp III and NYSE debut.
    • MillerKnoll, Inc. (NASDAQ:MLKN) shares fell 17.4% to $25.19 in pre-market trading as the company reported downbeat sales for its third quarter and issued weak guidance for the fourth quarter.
    • Gamida Cell Ltd. (NASDAQ:GMDA) shares tumbled 16.6% to $0.0494 in pre-market trading. Gamida Cell shares dipped over 82% on Wednesday after the company reported fourth-quarter results and disclosed the commencement of a restructuring process.
    • urban-gro, Inc. (NASDAQ:UGRO) declined 16.3% to $1.5196 in pre-market trading after the company reported worse-than-expected fourth-quarter financial results.
    • Movella Holdings Inc. (NASDAQ:MVLA) fell 15.2% to $0.0640 pre-market trading after dipping 20% on Wednesday.
    • NuCana plc (NASDAQ:NCNA) fell 13.4% to $0.2702 in pre-market trading. NuCana announced a plan to implement 1-for-25 ADS ratio change.
    • The Chemours Company (NYSE:CC) shares dropped 10% to $26.00 in pre-market trading after the company reported fourth-quarter results. The company also disclosed material weaknesses and remediation plan .
    • Abits Group Inc. (NASDAQ:ABTS) fell 9.2% to $0.7083 in pre-market trading.
    • Hitek Global Inc. (NASDAQ:HKIT) fell 8.1% to $1.60 in pre-market trading after gaining over 22% on Wednesday.
    • SOBR Safe, Inc. (NASDAQ:SOBR) fell 8% to $0.46 pre-market trading after gaining 12% on Wednesday.

     

    Now Read This: RH, Walgreens And 3 Stocks To Watch Heading Into Thursday

     

    Get the next $ABTS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABTS
    $AKBA
    $AVTX
    $CC

    CompanyDatePrice TargetRatingAnalyst
    MillerKnoll Inc.
    $MLKN
    2/10/2026Outperform
    William Blair
    Avalo Therapeutics Inc.
    $AVTX
    2/2/2026$50.00Buy
    Guggenheim
    Avalo Therapeutics Inc.
    $AVTX
    12/18/2025$39.00Outperform
    Mizuho
    RH
    $RH
    12/12/2025$165.00Buy → Hold
    Stifel
    RH
    $RH
    12/12/2025$220.00 → $185.00Market Perform
    Telsey Advisory Group
    RH
    $RH
    10/2/2025Outperform → Mkt Perform
    William Blair
    Avalo Therapeutics Inc.
    $AVTX
    9/17/2025$15.00 → $25.00Buy
    H.C. Wainwright
    RH
    $RH
    9/12/2025$220.00Outperform → Market Perform
    Telsey Advisory Group
    More analyst ratings

    $ABTS
    $AKBA
    $AVTX
    $CC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    The Chemours Company Announces Upsizing and Pricing of Private Offering of $700,000,000 of 7.875% Senior Notes Due 2034

    WILMINGTON, Del., Feb. 26, 2026 /PRNewswire/ -- The Chemours Company (Chemours) (NYSE: CC) today announced the pricing of its previously announced private offering of $700,000,000 aggregate principal amount of new 7.875% senior notes due 2034 (the "Notes"). The offering size was increased from the previously announced offering size of $600,000,000 aggregate principal amount of Notes. The Notes will bear interest at 7.875% per annum and mature on March 15, 2034. Interest on the Notes will be payable semi-annually on March 15 and September 15 of each year, beginning on September 15, 2026. The Notes will be senior unsecured obligations of Chemours and will be guaranteed by certain of its subsid

    2/26/26 4:39:00 PM ET
    $CC
    Major Chemicals
    Industrials

    The Chemours Company Announces Private Offering of $600,000,000 of Senior Notes Due 2034

    WILMINGTON, Del., Feb. 26, 2026 /PRNewswire/ -- The Chemours Company ("Chemours") (NYSE:CC) today announced that it intends to offer $600,000,000 aggregate principal amount of new senior notes due 2034 (the "Notes"), subject to market and other conditions. The Notes will be senior unsecured obligations of Chemours and will be guaranteed by a subsidiary of Chemours. Chemours intends to use the net proceeds from the offering to fund the redemption of its outstanding 5.375% senior notes due 2027 and to fund the redemption or repurchase of a portion of its outstanding 5.750% senior notes due 2028. 

    2/26/26 8:58:00 AM ET
    $CC
    Major Chemicals
    Industrials

    GigaCloud Technology Inc Announces Fourth Quarter and Year Ended December 31, 2025 Financial Results

    —Delivering Record Revenue and EPS— EL MONTE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- GigaCloud Technology Inc (NASDAQ:GCT) ("GigaCloud" or the "Company"), a pioneer of global end-to-end B2B ecommerce technology solutions for large parcel merchandise, today announced financial results for the fourth quarter and fiscal year ended December 31, 2025, highlighted by record revenues and EPS. Fourth Quarter 2025 Financial Highlights Total revenues of $362.7 million, increased 22.7% year-over-year.Gross profit of $82.9 million, increased 27.5% year-over-year. Gross margin was 22.9%, compared to 22.0% in the fourth quarter of 2024.Net income of $38.5 million, increased 24.2% year-over-year.N

    2/26/26 7:00:00 AM ET
    $GCT
    Catalog/Specialty Distribution
    Consumer Discretionary

    $ABTS
    $AKBA
    $AVTX
    $CC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Baluch Khoso bought 11,766 shares, increasing direct ownership by 29% to 52,516 units (SEC Form 4)

    4 - Longeveron Inc. (0001721484) (Issuer)

    8/13/25 6:00:07 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Locklear Lisa bought 11,766 shares, increasing direct ownership by 5% to 250,964 units (SEC Form 4)

    4 - Longeveron Inc. (0001721484) (Issuer)

    8/13/25 6:00:08 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Dignam Denise bought $49,060 worth of shares (4,068 units at $12.06) (SEC Form 4)

    4 - Chemours Co (0001627223) (Issuer)

    8/12/25 5:12:16 PM ET
    $CC
    Major Chemicals
    Industrials

    $ABTS
    $AKBA
    $AVTX
    $CC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    William Blair initiated coverage on MillerKnoll

    William Blair initiated coverage of MillerKnoll with a rating of Outperform

    2/10/26 8:01:31 AM ET
    $MLKN
    Office Equipment/Supplies/Services
    Consumer Discretionary

    Guggenheim initiated coverage on Avalo Therapeutics with a new price target

    Guggenheim initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $50.00

    2/2/26 6:51:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mizuho initiated coverage on Avalo Therapeutics with a new price target

    Mizuho initiated coverage of Avalo Therapeutics with a rating of Outperform and set a new price target of $39.00

    12/18/25 9:07:24 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABTS
    $AKBA
    $AVTX
    $CC
    SEC Filings

    View All

    SEC Form S-8 filed by SOBR Safe Inc.

    S-8 - SOBR Safe, Inc. (0001425627) (Filer)

    2/27/26 5:14:59 PM ET
    $SOBR
    Newspapers/Magazines
    Consumer Discretionary

    Chemours Company filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Chemours Co (0001627223) (Filer)

    2/26/26 4:56:13 PM ET
    $CC
    Major Chemicals
    Industrials

    SEC Form 10-K filed by Akebia Therapeutics Inc.

    10-K - Akebia Therapeutics, Inc. (0001517022) (Filer)

    2/26/26 7:35:08 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABTS
    $AKBA
    $AVTX
    $CC
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for VAFSEO issued to AKEBIA THERAPEUTICS INC

    Submission status for AKEBIA THERAPEUTICS INC's drug VAFSEO (ORIG-1) with active ingredient VADADUSTAT has changed to 'Approval' on 03/27/2024. Application Category: NDA, Application Number: 215192, Application Classification: Type 1 - New Molecular Entity

    3/28/24 10:46:38 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    April 17, 2023 - FDA Approves Cell Therapy for Patients with Blood Cancers to Reduce Risk of Infection Following Stem Cell Transplantation

    For Immediate Release: April 17, 2023 Today, the U.S. Food and Drug Administration approved Omisirge (omidubicel-onlv), a substantially modified allogeneic (donor) cord blood-based cell therapy to quicken the recovery of neutrophils (a subset of white blood cells) in the body and reduce the risk of infection. The product is intended for use in adults and pediatric patients 12 years and older with blood cancers p

    4/17/23 1:02:15 PM ET
    $GMDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    December 23, 2021 - FDA Authorizes Marketing of Tobacco Products that Help Reduce Exposure to and Consumption of Nicotine for Smokers Who Use Them

    For Immediate Release: December 23, 2021 Today, the U.S. Food and Drug Administration authorized the marketing of 22nd Century Group Inc.’s “VLN King” and “VLN Menthol King” combusted, filtered cigarettes as modified risk tobacco products (MRTPs), which help reduce exposure to, and consumption of, nicotine for smokers who use them. These are the first combusted cigarettes to be authorized as MRTPs and the second

    12/23/21 9:06:12 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $ABTS
    $AKBA
    $AVTX
    $CC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, GC & Corp. Secretary Wellman Kristine M was granted 1,781 shares and covered exercise/tax liability with 675 shares, increasing direct ownership by 2% to 51,402 units (SEC Form 4)

    4 - Chemours Co (0001627223) (Issuer)

    2/26/26 6:00:08 PM ET
    $CC
    Major Chemicals
    Industrials

    Chief Execitive Officer Dignam Denise was granted 2,261 shares and covered exercise/tax liability with 742 shares, increasing direct ownership by 0.81% to 187,996 units (SEC Form 4)

    4 - Chemours Co (0001627223) (Issuer)

    2/26/26 6:00:03 PM ET
    $CC
    Major Chemicals
    Industrials

    Director Visser Jan William was granted 808 units of Class A Ordinary Shares, increasing direct ownership by 7% to 12,106 units (SEC Form 4)

    4 - GigaCloud Technology Inc (0001857816) (Issuer)

    2/17/26 8:42:41 PM ET
    $GCT
    Catalog/Specialty Distribution
    Consumer Discretionary

    $ABTS
    $AKBA
    $AVTX
    $CC
    Leadership Updates

    Live Leadership Updates

    View All

    Longeveron® Appoints Stephen H. Willard as Chief Executive Officer

    Mr. Willard has a 30+ year track record of leadership across public and private sectors as CEO of multiple biotechnology and pharmaceutical firms, with an impressive history of delivering significant fundraises and strategic collaborationsCorporate focus on delivering top-line results from the pivotal Phase 2b clinical trial in Hypoplastic Left Heart Syndrome (HLHS), anticipated in the third quarter of 2026 Than Powell stepped down as interim CEO; will remain with the Company to support the leadership transition and continue his work in the Company's on-going business development activities MIAMI, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerati

    2/13/26 4:30:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MillerKnoll Appoints Former J. Jill CEO Claire Spofford to Board of Directors

    ZEELAND, Mich., Jan. 16, 2026 /PRNewswire/ -- MillerKnoll (NASDAQ:MLKN), a growth-oriented small-cap value company in the industrial and consumer sectors, today appointed Claire Spofford to its Board of Directors. An accomplished retail executive with more than 30 years of experience driving growth across leading consumer brands, Spofford brings deep expertise in omnichannel strategy, brand development, and operational excellence. She most recently served as President and Chief Executive Officer of J. Jill, where she helped transform the business, strengthened margins and refr

    1/16/26 4:05:00 PM ET
    $MLKN
    Office Equipment/Supplies/Services
    Consumer Discretionary

    NuCana Appoints Theresa Bruce as Chief Operating Officer

    EDINBURGH, United Kingdom, Jan. 06, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) ("NuCana" or the "Company"), a clinical-stage biopharmaceutical company focused on improving treatment outcomes for patients with cancer, announced the appointment of Theresa Bruce as Chief Operating Officer, effective January 1, 2026. "We are delighted to appoint Theresa as Chief Operating Officer and welcome her to NuCana's executive leadership team," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "Theresa brings more than two decades of experience leading global clinical development programs across biotechnology companies and clinical research organizations. Her operational leade

    1/6/26 8:00:00 AM ET
    $NCNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABTS
    $AKBA
    $AVTX
    $CC
    Financials

    Live finance-specific insights

    View All

    GigaCloud Technology Inc Announces Fourth Quarter and Year Ended December 31, 2025 Financial Results

    —Delivering Record Revenue and EPS— EL MONTE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- GigaCloud Technology Inc (NASDAQ:GCT) ("GigaCloud" or the "Company"), a pioneer of global end-to-end B2B ecommerce technology solutions for large parcel merchandise, today announced financial results for the fourth quarter and fiscal year ended December 31, 2025, highlighted by record revenues and EPS. Fourth Quarter 2025 Financial Highlights Total revenues of $362.7 million, increased 22.7% year-over-year.Gross profit of $82.9 million, increased 27.5% year-over-year. Gross margin was 22.9%, compared to 22.0% in the fourth quarter of 2024.Net income of $38.5 million, increased 24.2% year-over-year.N

    2/26/26 7:00:00 AM ET
    $GCT
    Catalog/Specialty Distribution
    Consumer Discretionary

    Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights

    Q4 2025 net product revenues of $54.3 million; 2025 full-year net product revenues of $227.3 million, representing a 49% increase over 2024 full-year net product revenues Expect significant Vafseo® (vadadustat) revenue growth in 2026 through expanded access to therapy at dialysis organizations, new patient starts, and improved adherence rates Pipeline advancement continues with enrollment underway for praliciguat Phase 2 clinical trial in focal segmental glomerulosclerosis (FSGS) and AKB-097 Phase 2 rare kidney disease basket trial planned to begin in 2H 2026 Akebia to Host Conference Call at 8:00 a.m. EST on February 26, 2026 CAMBRIDGE, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Ake

    2/26/26 7:00:00 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MillerKnoll Schedules Third Quarter Fiscal Year 2026 Conference Call and Webcast

    ZEELAND, Mich., Feb. 25, 2026 /PRNewswire/ -- MillerKnoll, Inc. ("MillerKnoll" or the "Company") (NASDAQ:MLKN), a growth-oriented small-cap value company in the industrial and consumer sectors, will release its third quarter fiscal 2026 results on Wednesday, March 25, 2026, after market close. A conference call and webcast to discuss the Company's financial and operational results and answer questions from the investment community will follow at 5:00 p.m. Eastern time. Investors will be able to access the press release and supporting materials on the Company's investor relations

    2/25/26 4:05:00 PM ET
    $MLKN
    Office Equipment/Supplies/Services
    Consumer Discretionary

    $ABTS
    $AKBA
    $AVTX
    $CC
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at urban-gro Inc. on Jun 6

    Urban-gro Inc. saw an interesting insider purchase on June 6, 2024, when Wilks Lewis bought $29,000 worth of shares, acquiring 20,000 units at a price of $1.45 per unit. This transaction increased Lewis' direct ownership by 12% to 184,108 units, as reported in SEC Form 4. Insider transactions like this can provide valuable insights for investors, indicating confidence in the company's future prospects. Analyzing the insider activity surrounding Urban-gro Inc., we can observe several transactions that may reveal patterns or insights. Looking back at previous filings, on September 1, 2023, Wilks Lewis purchased $10,300 worth of shares, acquiring 10,000 units at $1.03 per unit. This

    6/10/24 12:49:49 AM ET
    $UGRO
    Industrial Specialties
    Consumer Discretionary

    $ABTS
    $AKBA
    $AVTX
    $CC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by GigaCloud Technology Inc

    SC 13D/A - GigaCloud Technology Inc (0001857816) (Subject)

    12/12/24 3:02:53 PM ET
    $GCT
    Catalog/Specialty Distribution
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by 22nd Century Group Inc.

    SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)

    12/3/24 11:18:54 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SC 13D/A filed by Abits Group Inc

    SC 13D/A - Abits Group Inc (0001864055) (Subject)

    11/21/24 6:05:10 PM ET
    $ABTS
    Computer Software: Programming Data Processing
    Technology